|
Kathy LaPorte is a Managing Director and concentrates on our
pharmaceutical companies. Kathy joined the Sprout Group in 1993
and became a General Partner in 1994. Between 1987 and 1993,
she was a Principal at Asset Management Company, a venture
capital firm focused on early stage investments. Previously,
she was a financial analyst with The First Boston
Corporation. Ms. LaPorte's focus is on biopharmaceutical and
diagnostic investments. She is the Past President, and a
former member of the Board of the Western Association of Venture
Capitalists. Ms. LaPorte received an MBA from Stanford
University Graduate School of Business (Arjay Miller
Scholar), and a BS, summa cum laude, Phi Beta Kappa from
Yale University.
Board Seats:
Aesthetic Sciences,
Affymax (AFFY),
ISTA Pharmaceuticals (ISTA),
Pearl Therapeutics,
Prometheus Laboratories,
Transcept Pharmaceuticals,
VNUS Medical Technologies (VNUS)
Contact Information:
kathy@nlvpartners.com
(650) 234-2700
|
 |
